Abstract
A 40-year-old male with an 8-year history of psoriasis and psoriatic arthritis presented to the clinic after discontinuing his medication following a herpes zoster outbreak 2 months ago. The shingles rash is completely resolved, and he denied residual pain, sensitivity to light touch, itching, or numbness. Before the infection, the patient’s psoriasis was moderately controlled with etanercept. The patient denied experiencing adverse side effects with etanercept. Since stopping the medication, he believed his psoriasis had worsened with new lesions appearing on his face, scalp, and extremities. He was interested in restarting a biologic agent as previous attempts with phototherapy and methotrexate were not beneficial. He was otherwise healthy and did not use other medications. He has a family history of psoriasis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28(7):846–52. doi:10.1111/jdv.12307.
Bolognia J, Schaffer JV, Duncan KO, Ko CJ. Dermatology essentials. Oxford: Saunders and Elsevier; 2014.
Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26(9):1127–32. doi:10.1111/j.1468-3083.2011.04230.x.
Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30. quiz CE2–4.
Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, Feldhamer I, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151(5):533–8. doi:10.1001/jamadermatol.2014.4956.
Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–95. doi:10.1001/jama.2013.1099.
Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Pun, S., Amin, M., No, D.J., Wu, J.J. (2017). Herpes Zoster Reactivation in a 40-Year-Old with Psoriasis. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-52779-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-52779-6_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52778-9
Online ISBN: 978-3-319-52779-6
eBook Packages: MedicineMedicine (R0)